A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Biological: JTR-161Biological: Placebo
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Teijin Pharma Limited
- Target Recruit Count
- 79
- Registration Number
- NCT04608838
- Locations
- 🇯🇵
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath